[go: up one dir, main page]

SG10201609364QA - Liquid formulation - Google Patents

Liquid formulation

Info

Publication number
SG10201609364QA
SG10201609364QA SG10201609364QA SG10201609364QA SG10201609364QA SG 10201609364Q A SG10201609364Q A SG 10201609364QA SG 10201609364Q A SG10201609364Q A SG 10201609364QA SG 10201609364Q A SG10201609364Q A SG 10201609364QA SG 10201609364Q A SG10201609364Q A SG 10201609364QA
Authority
SG
Singapore
Prior art keywords
liquid formulation
formulation
liquid
Prior art date
Application number
SG10201609364QA
Inventor
Nicholas Bova
Stephen Page
Giuseppe Pippia
Original Assignee
Luoda Pharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902062A external-priority patent/AU2012902062A0/en
Application filed by Luoda Pharma Pty Ltd filed Critical Luoda Pharma Pty Ltd
Publication of SG10201609364QA publication Critical patent/SG10201609364QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201609364QA 2012-05-18 2013-05-17 Liquid formulation SG10201609364QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2012902062A AU2012902062A0 (en) 2012-05-18 Liquid Formulation

Publications (1)

Publication Number Publication Date
SG10201609364QA true SG10201609364QA (en) 2017-01-27

Family

ID=49582909

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201703789QA SG10201703789QA (en) 2012-05-18 2013-05-17 Liquid formulation
SG10201609364QA SG10201609364QA (en) 2012-05-18 2013-05-17 Liquid formulation
SG11201407200TA SG11201407200TA (en) 2012-05-18 2013-05-17 Liquid formulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201703789QA SG10201703789QA (en) 2012-05-18 2013-05-17 Liquid formulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201407200TA SG11201407200TA (en) 2012-05-18 2013-05-17 Liquid formulation

Country Status (17)

Country Link
US (3) US9808529B2 (en)
EP (2) EP3682902A1 (en)
JP (2) JP2015516441A (en)
KR (1) KR102041654B1 (en)
CN (2) CN109568253B (en)
AU (1) AU2013262438B2 (en)
BR (1) BR112014028602B1 (en)
CA (1) CA2873502C (en)
CL (1) CL2014003121A1 (en)
CO (1) CO7160059A2 (en)
IN (1) IN2014MN02271A (en)
MX (1) MX369832B (en)
NZ (2) NZ724002A (en)
RU (1) RU2640023C2 (en)
SG (3) SG10201703789QA (en)
WO (1) WO2013170317A1 (en)
ZA (1) ZA201409269B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
AU2013262438B2 (en) 2012-05-18 2017-03-16 Luoda Pharma Limited Liquid formulation
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
DK3021832T3 (en) * 2013-07-19 2021-05-25 Boehringer Ingelheim Vetmedica Gmbh PRESERVED ETHERIFIED CYCLODEXTRINE DERIVATIVES CONTAINING LIQUID AQUATIC PHARMACEUTICAL COMPOSITION
DK3106150T3 (en) * 2013-12-04 2021-11-01 Boehringer Ingelheim Vetmedica Gmbh IMPROVED PHARMACEUTICAL COMPOSITIONS OF PIMOBENDAN
CN104161756B (en) * 2014-06-13 2017-02-01 河北智同医药控股集团有限公司 Olprinone hydrochloride injection composition
US10350223B2 (en) 2015-03-03 2019-07-16 Richard W. Yee Compositions and methods for treating ocular diseases
CN105029678A (en) * 2015-07-24 2015-11-11 广东中烟工业有限责任公司 Tobacco composite additive and application thereof
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN106729723A (en) * 2016-11-21 2017-05-31 青岛农业大学 A kind of pharmaceutical composition containing UD-CG115BS.acardi and preparation method thereof
PL3609486T3 (en) * 2017-04-11 2021-11-29 Ceva Santé Animale SARPOGRELATE FOR THE TREATMENT OF HEART DISEASE IN MAMMALIES
US10954115B2 (en) * 2017-12-18 2021-03-23 Maxum Enterprises, Llc System and method for delivering fuel
FR3077984B1 (en) * 2018-02-16 2020-02-21 Vetoquinol Sa MULTI-PURPOSE COMPOSITION OF TORASEMIDE
WO2020039262A1 (en) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceuticals solution for oral dosage
CA3128033A1 (en) * 2019-01-31 2020-08-06 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
JP2022534960A (en) * 2019-05-28 2022-08-04 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Diazepinone derivatives as capsid assembly modifiers
CN111803468B (en) * 2020-06-23 2022-12-23 黑龙江天龙药业有限公司 Nasal cavity film spraying agent for targeting, slow-release, film-forming and virus and bacteria inhibiting and preparation method thereof
KR102663470B1 (en) 2023-03-16 2024-05-10 주식회사 케어사이드 Composition for prevention of heart disease by pulmonary hypertension and treatment of heart function and functional formulation comprising the same
CN117538462B (en) * 2024-01-10 2024-03-26 地奥集团成都药业股份有限公司 Method for detecting related substances of amlodipine benazepril capsules

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05262650A (en) 1992-03-18 1993-10-12 Meiji Seika Kaisha Ltd Stable composition for injection
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
GB9717444D0 (en) * 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
FI109659B (en) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Pharmaceutical solutions of levosimendan
KR100452972B1 (en) * 2000-05-16 2004-10-14 주식회사 삼양사 Hydrogel composition for transdermal drug
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6706563B2 (en) 2002-04-10 2004-03-16 St Assembly Test Services Pte Ltd Heat spreader interconnect methodology for thermally enhanced PBGA packages
JP2006514119A (en) 2003-02-12 2006-04-27 アール アンド ピー コリア カンパニー リミテッド Solvent system of poorly soluble drugs with improved dissolution rate
HUP0300985A2 (en) 2003-04-15 2005-07-28 SynoSens Kutató és Fejlesztő Kft. Pharmaceutical composition having improved spectrum
US9259390B2 (en) * 2003-08-13 2016-02-16 The University Of Houston System Parenteral and oral formulations of benzimidazoles
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
KR20080016527A (en) * 2005-01-31 2008-02-21 밀란 래보러토리즈, 인크. Pharmaceutical Compositions Containing Hydroxylated Nebivolol
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007067470A2 (en) * 2005-12-06 2007-06-14 Wyeth Benzimidazole non-aqueous compositions
JP4572300B2 (en) 2006-01-19 2010-11-04 トーアエイヨー株式会社 Pimobendan oral dosage formulation
KR20070076769A (en) * 2006-01-20 2007-07-25 일양약품주식회사 Injectable composition of amlodipine and preparation method thereof
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
WO2008082871A1 (en) 2006-12-28 2008-07-10 Orion Corporation Formulations of levosimendan for parenteral administration
WO2009061529A1 (en) 2007-11-06 2009-05-14 Tap Pharmaceutical Products, Inc. (+)-enantiomer of 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole and processing method eor preparing the same
US20090270356A1 (en) * 2008-04-28 2009-10-29 Ceva Sante Animale Sa Compositions and treatments of heart failure in non-human mammal animals
AU2010100349B4 (en) 2009-04-15 2012-03-29 Jurox Pty Ltd Anthelmintic formulation
JP2011006380A (en) * 2009-05-22 2011-01-13 Mochida Pharmaceut Co Ltd EMULSIFIED COMPOSITION OF ω3 FATTY ACID
NL2006622C2 (en) * 2011-04-18 2012-10-22 Eurovet Animal Health B V Use of a composition comprising torasemide.
AU2013262438B2 (en) 2012-05-18 2017-03-16 Luoda Pharma Limited Liquid formulation

Also Published As

Publication number Publication date
CA2873502A1 (en) 2013-11-21
MX369832B (en) 2019-11-22
US11357855B2 (en) 2022-06-14
US20190381175A1 (en) 2019-12-19
EP2849792B1 (en) 2020-03-04
RU2640023C2 (en) 2017-12-25
CL2014003121A1 (en) 2015-07-24
ZA201409269B (en) 2017-02-22
EP2849792A4 (en) 2015-12-16
JP2017061512A (en) 2017-03-30
JP6448001B2 (en) 2019-01-09
CA2873502C (en) 2017-09-12
WO2013170317A1 (en) 2013-11-21
SG10201703789QA (en) 2017-06-29
JP2015516441A (en) 2015-06-11
NZ724002A (en) 2017-07-28
IN2014MN02271A (en) 2015-07-24
CN109568253B (en) 2022-04-26
SG11201407200TA (en) 2014-12-30
KR102041654B1 (en) 2019-11-06
BR112014028602A2 (en) 2017-06-27
CN104619345A (en) 2015-05-13
US10413610B2 (en) 2019-09-17
BR112014028602B1 (en) 2023-10-24
CN109568253A (en) 2019-04-05
US20180028665A1 (en) 2018-02-01
HK1208372A1 (en) 2016-03-04
NZ701609A (en) 2016-09-30
AU2013262438A1 (en) 2014-11-20
EP2849792A1 (en) 2015-03-25
EP3682902A1 (en) 2020-07-22
US20150148335A1 (en) 2015-05-28
AU2013262438B2 (en) 2017-03-16
CO7160059A2 (en) 2015-01-15
US9808529B2 (en) 2017-11-07
RU2014145136A (en) 2016-07-10
MX2014013871A (en) 2015-05-12
KR20150024337A (en) 2015-03-06

Similar Documents

Publication Publication Date Title
ZA201409269B (en) Liquid formulation
IL235966A0 (en) Antibody formulation
IL237804A0 (en) Apixaban liquid formulations
EP2894033A4 (en) Liquid drop-discharging device
SG11201407759SA (en) Liquid distribution device
ZA201306000B (en) Stable formulation
ZA201409020B (en) Pharmaceutical formulation
EP2905325A4 (en) Liquid detergent
GB201302688D0 (en) Detergent formulation
GB201205562D0 (en) Liquid insecticidal compositions
GB201201162D0 (en) Liquid cosmetic composition
EP2875837A4 (en) Liquid administration tool
ZA201502036B (en) Liquid insecticidal composition
PT2662093E (en) Tobramycin formulation
IL233440B (en) Stand mixers
EP2928903A4 (en) Oligonucleotide formulation
EP2800474A4 (en) Coffee formulation
EP2772141A4 (en) Liquid sweetener composition
EP2830607A4 (en) Polyvinylpyrrolidone-containing acetaminophen liquid formulations
IL235539B (en) Liquid atomizer
SG11201406097SA (en) Capsule formulation
ZA201406407B (en) Pharmaceutical formulation containing flupirtin
AU2012902062A0 (en) Liquid Formulation
GB201211247D0 (en) Improved formulation
AP00764S1 (en) Liquid applicator